You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 4, 2026

Surprise Inside! Thai Regulations for Food Products with Randomized Toys

Subscribe to Updates

Blind boxes and collectibles have become increasingly popular, driven by the excitement of not knowing which character or design will be revealed until the package is opened. While most visible in the art toy market, the same concept is also used in the food industry.

Confectionery, snacks, and other food products are sometimes sold with toys, character figures, cards, or other collectibles. A package might, for example, contain one of ten possible characters, with consumers knowing that an item is included but not which one they will receive. Some collections may also feature rare or “secret” items.

For food businesses, however, adding a randomized toy or collectible involves more than a marketing decision. The food, the nonfood item, and the randomized mechanism may each raise different regulatory considerations in Thailand.

Thai FDA Requirements for Nonfood Objects Packaged with Food

The main food regulatory consideration is Ministry of Public Health Notification No. 310 B.E. 2551 (2008), which regulates food packaged together with things or objects that are not food. Under Notification No. 310, certain nonfood objects may be packaged together with food where they fall within specified exceptions, including objects that serve the following purposes:

  • Maintaining the quality or standard of the food, such as a desiccant or oxygen absorber;
  • Serving as a seasoning or as part of food preparation, such as chili powder sachets or seasoning sachets contained in instant noodle packages; or
  • Functioning as an eating or food-preparation utensil, such as a spoon or fork included with instant noodles.

Other nonfood objects that do not fall within these categories generally should not be placed inside the food container together with the food. Where a toy, collectible, or other nonfood object is intended to be sold together with a food product, businesses should therefore carefully consider the nature of the object, how it is packaged and separated from the food, and the applicable Thai FDA requirements on a case-by-case basis.

In practice, the packaging arrangement should be assessed to ensure that the nonfood object does not create a health risk or cause consumers to mistakenly believe that it is edible. Depending on the specific packaging arrangement, this may involve placing the nonfood item outside the immediate food container, separately packaging it within the overall package, clearly separating the respective compartments, or attaching the promotional item externally to the food package.

When the Randomized Item Is a Toy

Where the nonfood item is a toy, a separate regulatory regime may also apply. Toys intended for children under 14 years of age may be subject to Thailand’s mandatory product safety requirements administered by the Thai Industrial Standards Institute (TISI), including TIS 685 on toys, depending on the characteristics and classification of the product. These requirements apply separately from the Thai FDA requirements applicable to the food and its packaging.

This is particularly relevant for imported products. A food product may need to satisfy Thai FDA requirements, while a toy included with it may separately require compliance with applicable TISI requirements.

In practice, businesses should therefore assess both the packaging arrangement under Thai FDA requirements and the toy itself under the applicable product safety requirements.

Randomized Toys, Different Values, and Other Legal Considerations

In situations where the toys are randomized, the fact that consumers do not know which toy they will receive does not, by itself, change the food regulatory analysis under Notification No. 310. Nor does the presence of randomness necessarily mean that the arrangement constitutes gambling.

However, separate legal considerations may arise depending on how the randomized mechanism is structured and marketed. One relevant factor may be the relative commercial value of the possible items. If the possible items have materially different values, the arrangement may raise different considerations than situations where the items are of broadly comparable value and the random element is primarily which character or design the consumer receives. For example, if most packages contain ordinary figures while a small number contain rare or “secret” items of substantially higher value, the difference in value may become relevant to the gambling-law analysis. Even where every consumer is guaranteed to receive an item, the element of chance may determine whether the item received is worth less than, equal to, or more than the amount paid. This may raise considerations relating to the risk of gaining or losing value under Thailand’s Gambling Act B.E. 2478 (1935), as the nature and value of the possible items, whether any additional prize or premium is offered by chance, and the overall structure of the promotion may also be relevant.

A related issue may arise where additional prizes or premiums are randomly included with the purchased product. Depending on the structure, this may fall within the provisions of the Gambling Act concerning the offering of premiums or prizes by chance, for which prior permission may be required.

The treatment of claw machines provides a useful comparison. Under the Gambling Act, as amended, certain amusement machines capable of producing a win-or-lose outcome may fall within the gambling regulatory framework. In a conventional claw-machine arrangement, a player pays for each attempt but may receive nothing if unsuccessful. The outcome therefore determines whether the player receives an item at all.

When assessing the regulatory implications of randomized items, the analysis should consider the overall structure of the transaction, including whether the consumer is guaranteed to receive an item, the relative value of the possible items, the role of chance in determining the outcome, and how the promotion is structured and marketed. Whether a particular arrangement raises issues under the Gambling Act will ultimately depend on its specific circumstances and should be assessed separately on a case-by-case basis.

One Product, Multiple Regulatory Considerations

A food product containing a randomized toy may appear to consumers as a single product, but businesses may need to consider several regulatory layers: Thai FDA requirements for the food and the packaging of a nonfood object with it, TISI safety and compliance requirements applicable to the toy, and other applicable laws that may be relevant to the structure of any randomized or chance-based promotional mechanism.

Each regime addresses a different regulatory issue. Compliance with Thai FDA requirements, for example, has no bearing on whether the toy complies with TISI requirements or whether the promotional mechanism raises issues under other laws.

Key Takeaways for Food Businesses

As food brands increasingly use collectibles, character collaborations, and blind-box-style concepts, these regulatory considerations should be addressed early in product development.

For food products containing randomized toys, businesses should consider what the nonfood item is, how it is packaged with and separated from the food, whether separate product standards apply to the toy, and how any randomized mechanism is structured and promoted.

Where the possible collectibles have materially different relative commercial values, additional legal review may also be appropriate, particularly where the promotion emphasizes the chance of obtaining a rare or high-value item.

Ultimately, what appears to consumers as a simple “surprise inside” may involve several regulatory layers. Identifying these considerations early in product development can help food businesses address potential regulatory issues before the product reaches the Thai market.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

August 20, 2026
As part of its membership in Lex Mundi, Tilleke & Gibbins has released the latest edition of its Guide to Doing Business in Thailand, providing an overview of the legal, regulatory, and commercial considerations for companies establishing or expanding operations in Thailand. The 2026 edition offers practical insight into the country’s business environment, investment framework, and operational requirements. The guide covers a wide range of topics relevant to foreign and domestic investors, including: Investment incentives and promotion schemes Financial facilities and banking regulations Exchange controls and money transfers Import and export regulations Business structures and incorporation options Requirements for establishing a business Operational and compliance considerations Business cessation and insolvency procedures Employment and labor laws Taxation Immigration and visa requirements Prepared by Tilleke & Gibbins lawyers across multiple practice areas, the publication outlines key aspects of doing business in Thailand, including foreign investment restrictions, regulatory compliance obligations, corporate structures, employment requirements, and recent legal and economic developments affecting investors. The publication forms part of Lex Mundi’s Country Guides series, a global collection of jurisdiction-specific reference materials prepared by member firms around the world. Together, these guides help companies evaluate opportunities, compare regulatory environments, and plan international business activities across multiple markets. The full Guide to Doing Business in Thailand 2026 is available through the button below.
Read More
August 10, 2026
On June 17, 2026, Indonesia’s National Agency of Drug and Food Control (BPOM) issued BPOM Regulation No. 10 of 2026 on Nutritional Information on Processed Food Labels. The new regulation, which revokes three previous nutrition labeling regulations, introduces several notable changes affecting food and beverage manufacturers, importers, and distributors. These changes range from updated nutrient reference values and serving-size requirements to the introduction of the Nutri-Level front-of-pack labeling system for certain beverage products. Businesses operating in Indonesia should carefully review these developments and assess their products’ compliance with the new requirements during the transition period. Implementation of the Nutri-Level Labeling System To implement the recently issued decree on Nutri-Level labeling, BPOM Regulation No. 10 of 2026 stipulates the requirements to implement the Nutri-Level labeling system on the front-of-pack. Under the new framework, ready-to-drink beverages, powdered beverages, and liquid or solid concentrates are required to display Nutri-Level labeling on the front label of their packaging. The Nutri-Level labeling system classifies products into color-coded levels A through D based on their sugar, sodium, and total fat content. The applicable Nutri-Level is determined based on the lowest level measured in the assessment of sugar, sodium, and total fat content. For products classified as level C or D, the Nutri-Level label must be accompanied by information on the relevant sugar, sodium, and total fat content per 100 ml of the ready-to-consume product. Products classified as level A or B may either display only the Nutri-Level designation or display the Nutri-Level together with the relevant nutritional information per 100 ml. Minimum Vitamin and Mineral Content Required for Declaration BPOM Regulation No. 10 of 2026 introduces a stricter threshold for the declaration of vitamins and minerals in the nutritional value information section (ING). Vitamins or minerals may only be declared if they are present at a
Read More
August 10, 2026
The drug registration process in Vietnam will be simplified, particularly for foreign applicants, following the recent issuance by Vietnam’s Ministry of Health (MOH) of a new circular that is expected to reduce administrative hurdles. Circular No. 32/2026/TT-BYT on the registration of drugs and medicinal ingredients (Circular 32) was issued on July 29, 2026, and will take effect on October 1, 2026, replacing Circular No. 12/2025/TT-BYT. Key provisions of the new circular are discussed below. Five-Year Data Exclusivity and Five-Month Public Disclosure Framework Circular 32 updates data protection guidelines by explicitly referencing Article 128 of the amended Intellectual Property Law, which sets out that new drugs supported by clinical trial data submitted for the first time will be granted a five-year data exclusivity period from the date of the initial marketing authorization (MA) approval. Subsequent applications that rely on the originator’s protected data will not be eligible for approval from the date of submission of the originator’s registration dossier until five years after the first MA is granted. Furthermore, in accordance with the new regulations, the regulatory authority must publicly disclose information on subsequent applications five months before the granting of MA, providing originator companies with an opportunity to exercise and enforce their intellectual property rights. Simplified Requirements for Foreign Legal Documents Circular 32 expands the circumstances under which legal documents issued by foreign authorities are exempt from consular legalization and authenticity verification requirements. Specifically, such documents may be exempt if the Drug Administration of Vietnam (DAV) is able to verify their authenticity directly through official electronic means, including written confirmation or email correspondence sent directly to the MOH by the competent foreign authority, or publicly accessible English-language databases maintained by recognized foreign regulatory authorities. In addition, the new circular permits the submission of electronic notarized copies of legal documents
Read More
July 24, 2026
As food innovation continues to accelerate, manufacturers are increasingly introducing ingredients derived from new sources, produced using novel technologies, or lacking a significant history of human consumption. While these innovations create new opportunities for the food industry, they also raise important questions regarding consumer safety. For this reason, many jurisdictions, including Thailand, the European Union, Australia and New Zealand, Canada, and Singapore, require a premarket safety assessment for novel food ingredients before they can be placed on the market. The objective of this assessment is to ensure that each ingredient is safe for its intended use and level of consumption, does not present toxicological, allergenic, microbiological, or nutritional concerns, and will not mislead consumers. Scientific authorities typically evaluate the ingredient’s identity, manufacturing process, composition, specifications, anticipated dietary exposure, toxicological information, nutritional impact, and history of use before determining whether it can be marketed. Against this background, the Thai Food and Drug Administration (FDA) recently took an important step toward improving regulatory transparency by publishing, for the first time, a consolidated public list of substances that have successfully completed the Thai FDA’s safety assessment process, including substances determined to be novel foods and those determined not to fall within the novel food category. The list identifies the approved substances, the corresponding manufacturers or importers, approval dates, and the approved conditions of use. Although the publication does not change the existing legal framework governing novel food approvals, it provides businesses with greater visibility into the Thai FDA’s regulatory precedents and the types of substances that have previously been accepted through the safety assessment process. The full announcement is available on the Thai FDA’s website. As the list is now publicly available, it also provides useful insight into the types of substances that have successfully completed the Thai FDA’s safety assessment process.
Read More